Abstract
Two P388 cell lines with acquired resistance to daunorubicin have been shown to exhibit cross-resistance to anthrapyrazolone (NSC 357885). The degree of cross-resistance observed in these cell lines (58 and 150 fold) is similar to those observed towards daunorubicin (34 and 142 fold). However the decreased drug accumulation observed for daunorubicin in the resistant cell lines (4-6 fold) is not observed for anthrapyrazolone. Similarly, verapamil can increase daunorubicin accumulation in resistant cells but has no effect on anthrapyrazolone accumulation. It is concluded that in contrast to daunorubicin, decreased anthrapyrazolone accumulation is not the resistance mechanism operative in daunorubicin resistant cell lines towards anthrapyrazolone.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McGown, A., Poppitt, D. & Fox, B. Comparison of daunorubicin and anthrapyrazolone sensitivity and transport in resistant cell lines. Br J Cancer 56, 752–754 (1987). https://doi.org/10.1038/bjc.1987.283
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.283
This article is cited by
-
Effect of verapamil on daunorubicin accumulation in lymphocytes isolated from patients undergoing chemotherapy
Cancer Chemotherapy and Pharmacology (1991)
